JP Morgan Chase’s Avadel Pharmaceuticals AVDL Stock Holding History

JP Morgan Chase’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70,400	Closed	-$990K	–	7407
2024 Q2	$990K	Buy	+70,400	New	+$1.15M	﹤0.01%	4287
2023 Q3	–	Sell	-109,700	Closed	-$1.81M	–	7452
2023 Q2	$1.81M	Buy	109,700 +74,700	+213%	+$971K	﹤0.01%	3611
2023 Q1	$321K	Sell	35,000 -4,700	-12%	-$38.6K	﹤0.01%	4766
2022 Q4	$284K	Sell	39,700 -15,800	-28%	-$111K	﹤0.01%	4856
2022 Q3	$278K	Buy	+55,500	New	+$305K	﹤0.01%	4794
2020 Q2	–	Sell	-30,000	Closed	-$238K	–	5359
2020 Q1	$238K	Buy	+30,000	New	+$230K	﹤0.01%	4207

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's AVDL Position: Q1 2026 in Review

JP Morgan Chase sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 122,476 shares — an estimated $2.64M sold.

JP Morgan Chase first reported a position in AVDL in Q1 2014 and held it in 43 quarters. The position peaked at $20.3M in Q1 2014. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

JP Morgan Chase reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
JP Morgan Chase sold 122,476 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.64M.
JP Morgan Chase first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 43 quarters.
JP Morgan Chase's Avadel Pharmaceuticals position peaked at $20.3M in Q1 2014.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.